Evolving Role of Viltolarsen for Treatment of Duchenne Muscular Dystrophy
© 2024. The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature..
Duchenne muscular dystrophy (DMD) is one of the most prevalent X-linked inherited neuromuscular disorders, with an estimated incidence between 1 in 3500 and 5000 live male births. The median life expectancy at birth is around 30 years due to a rapid and severe disease progression. Currently, there is no cure for DMD, and the standard of care is mainly palliative therapy and glucocorticoids to mitigate symptoms and improve quality of life. Recent advances in phosphorodiamidate morpholino antisense oligonucleotide (PMO) technology has proven optimistic in providing a disease-modifying therapy rather than a palliative treatment option through correcting the primary genetic defect of DMD by exon skipping. However, as a result of the high variance in mutations of the dystrophin gene causing DMD, it has been challenging to tailor an effective therapy in most patients. Viltolarsen is effective in 8% of patients and accurately skips exon 53, reestablishing the reading frame and producing a functional form of dystrophin and milder disease phenotype. Results of recently concluded preclinical and clinical trials show significantly increased dystrophin protein expression, no severe adverse effects, and stabilization of motor function. In summary, viltolarsen has provided hope for those working toward giving patients a safe and viable treatment option for managing DMD. This review summarizes an overview of the presentation, pathophysiology, genetics, and current treatment guidelines of DMD, pharmacological profile of viltolarsen, and a summary of the safety and efficacy with additional insights using recent clinical trial data.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Advances in therapy - 41(2024), 4 vom: 20. März, Seite 1338-1350 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vincik, LeighAnn Y [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antisense therapy |
|---|
| Anmerkungen: |
Date Completed 25.03.2024 Date Revised 25.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12325-024-02801-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368667944 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368667944 | ||
| 003 | DE-627 | ||
| 005 | 20240325234911.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240220s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12325-024-02801-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1346.xml |
| 035 | |a (DE-627)NLM368667944 | ||
| 035 | |a (NLM)38376743 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vincik, LeighAnn Y |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evolving Role of Viltolarsen for Treatment of Duchenne Muscular Dystrophy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.03.2024 | ||
| 500 | |a Date Revised 25.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature. | ||
| 520 | |a Duchenne muscular dystrophy (DMD) is one of the most prevalent X-linked inherited neuromuscular disorders, with an estimated incidence between 1 in 3500 and 5000 live male births. The median life expectancy at birth is around 30 years due to a rapid and severe disease progression. Currently, there is no cure for DMD, and the standard of care is mainly palliative therapy and glucocorticoids to mitigate symptoms and improve quality of life. Recent advances in phosphorodiamidate morpholino antisense oligonucleotide (PMO) technology has proven optimistic in providing a disease-modifying therapy rather than a palliative treatment option through correcting the primary genetic defect of DMD by exon skipping. However, as a result of the high variance in mutations of the dystrophin gene causing DMD, it has been challenging to tailor an effective therapy in most patients. Viltolarsen is effective in 8% of patients and accurately skips exon 53, reestablishing the reading frame and producing a functional form of dystrophin and milder disease phenotype. Results of recently concluded preclinical and clinical trials show significantly increased dystrophin protein expression, no severe adverse effects, and stabilization of motor function. In summary, viltolarsen has provided hope for those working toward giving patients a safe and viable treatment option for managing DMD. This review summarizes an overview of the presentation, pathophysiology, genetics, and current treatment guidelines of DMD, pharmacological profile of viltolarsen, and a summary of the safety and efficacy with additional insights using recent clinical trial data | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Antisense therapy | |
| 650 | 4 | |a Duchenne muscular dystrophy | |
| 650 | 4 | |a Oligonucleotides | |
| 650 | 4 | |a PMO | |
| 650 | 4 | |a Viltolarsen | |
| 650 | 7 | |a viltolarsen |2 NLM | |
| 650 | 7 | |a SXA7YP6EKX |2 NLM | |
| 650 | 7 | |a Dystrophin |2 NLM | |
| 650 | 7 | |a Oligonucleotides |2 NLM | |
| 700 | 1 | |a Dautel, Alexandra D |e verfasserin |4 aut | |
| 700 | 1 | |a Staples, Abigail A |e verfasserin |4 aut | |
| 700 | 1 | |a Lauck, Lillian V |e verfasserin |4 aut | |
| 700 | 1 | |a Armstrong, Catherine J |e verfasserin |4 aut | |
| 700 | 1 | |a Howard, Jeffery T |e verfasserin |4 aut | |
| 700 | 1 | |a McGregor, David |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmadzadeh, Shahab |e verfasserin |4 aut | |
| 700 | 1 | |a Shekoohi, Sahar |e verfasserin |4 aut | |
| 700 | 1 | |a Kaye, Alan D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advances in therapy |d 1990 |g 41(2024), 4 vom: 20. März, Seite 1338-1350 |w (DE-627)NLM085859427 |x 1865-8652 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2024 |g number:4 |g day:20 |g month:03 |g pages:1338-1350 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12325-024-02801-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2024 |e 4 |b 20 |c 03 |h 1338-1350 | ||